---
schema_version: "secwatch.filing_event.v1"
accession: "0001671927-26-000026"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2026-09-14T11:15:04+00:00"
generated_at: "2026-09-14T11:21:34.098827+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunocore achieves 540-patient target enrollment in Phase 3 TEBE-AM trial of tebentafusp in post-PD1 melanoma

## Summary
- TEBE-AM enrolled 540 patients; randomized Phase 3 trial of tebentafusp ± pembrolizumab vs investigator's choice in HLA-A*02:01+ advanced melanoma.
- Primary endpoint overall survival; topline data expected as early as end of 2026.
- Trial targets previously treated post-PD1 advanced melanoma; potential addressable population ~4,000 patients in US/EU.
- Registrational trial; enrollment milestone supports KIMMTRAK expansion beyond first-line uveal melanoma.

## SEC filing metadata
- accession: 0001671927-26-000026
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2026-09-14T11:15:04+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000167192726000026/0001671927-26-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000167192726000026/imcr-20260914.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001671927-26-000026
- JSON: https://secwatch.observer/filing/0001671927-26-000026.json
- Plain text: https://secwatch.observer/filing/0001671927-26-000026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.